Canine Atopic Dermatitis Treatment Market Revenue to Reach US$ 2.4 Bn by 2029
The animal healthcare industry is becoming increasingly dynamic, and is no longer a market that goes easily unnoticed. It is witnessing attractiveness from external investors, including a stream of investments from players going beyond human health life sciences, driving digital innovations, as well as genetic and biotechnology development, into animal health. As innovations in veterinary science continue to spur the opportunity for novel drug development, global canine atopic dermatitis treatment market revenue will surge nearly fourfold by 2029, at an impressive pace.
Frequently Asked Questions about Canine Atopic Dermatitis Treatment Market
What are the factors contributing to the growth of the canine atopic dermatitis treatment market?
Increasing incidence of canine atopic dermatitis and growing adoption of pets in emerging countries such as China and India have resulted in propelling the demand for animal therapeutics, which has benefited the growth of the canine atopic dermatitis treatment market.
How are gaps in epidemiological knowledge hampering canine atopic dermatitis treatment market growth?
There exists a large gap in understanding the epidemiology pattern of veterinary diseases such as canine atopic dermatitis, due to variations in the disease pattern in certain endemic countries. This limits the development of multiple canine atopic dermatitis genotypes, hampering the discovery and production of novel vaccines.
What are the leading trends among end users contributing to the growth of the canine atopic dermatitis treatment market?
Drug manufacturers in the canine atopic dermatitis treatment market are taking comprehensive efforts to establish direct customer relations in order to understand unmet needs to develop new treatments for canine atopic dermatitis.
Which type of treatment has noteworthy growth potential during the forecast period??
Monoclonal antibodies are expected to witness relatively high demand, owing to significant biological efficacy in targeting canine atopic dermatitis.
Which region will offer lucrative opportunities for canine atopic dermatitis treatment market players?
East Asia is expected to show significant growth opportunities during the forecast period, owing to noteworthy industrial and infrastructural growth of bio-pharmaceutical companies in China and South Korea. Japan and China will remain the top two target geographies for drug manufacturers to expand their regional presence.
Who are the leading players in the canine atopic dermatitis treatment market?
The market is dominated by three major players - Elanco Animal Health, Merck KGaA, and Johnson & Johnson Services, Inc. These tier 1 players collectively hold 2/3 revenue share of the global canine atopic dermatitis treatment market.
Monoclonal Antibodies to Emerge as Pervasive Drug Class
At present, immunosuppressant drugs account for a pronounced share in the global canine atopic dermatitis treatment market. However, growing resistance to various therapeutic chemical agents are limiting their effectiveness, and, as such, their market share will partially stagnate in the coming years. Going forward, monoclonal antibodies (mAb) would emerge as a preferable drug class, owing to their high biological specificity in targeting canine atopic dermatitis. Although a newly developed drug class, mAbs will surpass immunosuppressant drugs in terms of value share during the latter half of the forecast period.
North America Market to Enter Billion-dollar Club in 2029
North America, on the back of rising pet ownership and strong presence of technology-forward healthcare infrastructure, continues to stay in the vanguard of the canine atopic dermatitis treatment market. Moreover, the developed regional market is likely to hit US$ 1 Bn mark by the end of 2029. Growing demand for animal healthcare services in Europe to improve food safety systems and veterinary public health in order to safeguard human health is also reflecting investment opportunities. For instance, Companion Insurance has been implemented to promote the efficiency of animal healthcare systems.
* This data is only a representation. Actual data may vary and will be available in report.
Flexible Ecosystem of Collaborations - Imperative for Bigger Gains
Canine atopic dermatitis treatment market players are focusing on entering into strategic collaborations for manufacturing veterinary vaccines. Boragen Inc., for instance, has inked an agreement with a leading animal health company for the discovery and development of canine atopic dermatitis treatment. This collaboration would aid the healthcare firm in producing advanced compounds targeting canine atopic dermatitis. Moreover, Immunomic Therapeutics Inc. has offered ZENOAQ an exclusive license to develop and commercialize its investigational DNA vaccine - ITI-002, for canine atopic dermatitis treatment.
Immuno- suppressant drugs take the lead
Monoclonal antibodies to showcase highest growth rate
Oral administration stays at the forefront
Injectable drugs see rapid adoption growth
Retail Pharmacies account for greater revenue share
Veterinary Clinics hold second-leading share
How Growth will Unfold
Oral administration of veterinary medicine is currently the preferred route for drug delivery to treat canine atopic dermatitis, leading with around half of total market revenue. However, towards the end of the projection period, it will lose its prominent status to injectable drug delivery in the canine atopic dermatitis treatment market. Witnessing triple-digit growth in its adoption in 2018, injectable administration of veterinary drugs is gaining rapid prominence, owing to lesser side effects and fast-paced recovery.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Canine Atopic Dermatitis Treatment Market Analysis 2019-2029
A recent market study published by Future Market Insights on the canine atopic dermatitis treatment market includes global industry analysis of 2014-2018 and opportunity assessment for 2019-2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the market, the growth prospects of the market are obtained with maximum precision.
Canine Atopic Dermatitis Treatment Market Taxonomy
The global canine atopic dermatitis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Essential Fatty Acids
- Monoclonal Antibodies
Mode of Administration
- Veterinary Hospitals
- Veterinary Clinics
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- North America
- Latin America
- East Asia
- South Asia
- Middle East and Africa (MEA)
The report initiates with the executive summary of the canine atopic dermatitis treatment market, which includes a summary of key findings and statistics of the market. It also includes supply-side and demand-side trends pertaining to the canine atopic dermatitis treatment market.
Readers can find the definition and a detailed segmentation of the canine atopic dermatitis treatment market in this chapter, which will help them understand the basic information about the canine atopic dermatitis treatment market. Along with this, comprehensive information pertaining to canine atopic dermatitis treatment is provided in this section. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the canine atopic dermatitis treatment market report.
This section explains the global market value analysis and forecast for the canine atopic dermatitis treatment market during the forecast period. This chapter includes a detailed analysis of the historical canine atopic dermatitis treatment market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029).
This section gives information about drivers and restraints of the canine atopic dermatitis treatment market. This section also includes macroeconomic factors and various opportunities of the canine atopic dermatitis treatment market.
Based on treatment type, the canine atopic dermatitis treatment market is segmented into corticosteroids, immunosuppressant, antibiotics, antihistamines, emollients, essential fatty acids, and Antipruritics. In this chapter, readers can find information about Y-o-Y growth and market attractiveness analysis based on treatment type.
Based on mode of administration, the canine atopic dermatitis treatment market is segmented into topical, oral and injectable. In this chapter, readers can understand the Y-o-Y growth and market attractiveness analysis based on mode of administration.
This chapter provides details about the canine atopic dermatitis treatment market based on the distribution channel, and has been classified into veterinary hospitals, veterinary clinics, retail pharmacies, drug stores, and mail over pharmacy. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.
This chapter explains how the canine atopic dermatitis treatment market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa.
This chapter includes a detailed analysis of growth of the North America canine atopic dermatitis treatment market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, and market growth based on the treatment type, mode of administration, distribution channel, and countries in North America.
This chapter provides the growth scenario of the canine atopic dermatitis treatment market in Latin American countries such as Brazil, Mexico, Argentina and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
Important growth prospects of the canine atopic dermatitis treatment market based on its end users in several countries such as the U.K., France, Germany, Spain, Italy, BENELUX, Russia and Rest of Europe are included in this chapter.
Important growth prospects of the canine atopic dermatitis treatment market across target segments in several countries such as China, Japan and South Korea are included in this chapter.
In this chapter, India, Indonesia, Thailand, Malaysia countries are the prominent countries in the South Asia region. Readers can find detailed information about the growth parameters of the South Asia canine atopic dermatitis treatment market during the forecast period of 2019-2029.
This section highlights the growth prospects of the canine atopic dermatitis treatment market for Australia and New Zealand, during the forecast period.
This chapter provides information about how the canine atopic dermatitis treatment market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period.
This chapter provides exclusive information about how the canine atopic dermatitis treatment market will grow in emerging countries China, Russia and India, during the forecast period of 2019-2029.
This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key player operating in canine atopic dermatitis treatment market.
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the canine atopic dermatitis treatment market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured are Elanco Animal Health (Eli Lily and Company), Ceva (Ceva Biovac), Zoetis Inc, Merck & Co., Inc., Virbac, Boehringer Ingelheim GmbH (Merial), Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Pfizer Inc.
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the canine atopic dermatitis treatment market report.
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the canine atopic dermatitis treatment market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Procurement Heads
- Sales Executives
- Raw Material Suppliers
- Industry Experts
- End Users
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Industry Publications & Associations
- World Veterinary Association
- American Academy of Veterinary Informatics
- American Association of Veterinary Immunologists
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
- Trade Websites
Primary Interview Splits